文献速递造血干细胞移植与细胞治疗淋巴瘤

慢性移植物抗宿主病治疗的新方法

Novel Approaches to the Treatment of Chronic Graft-Versus-Host Disease.
PubMed 文献 · J Clin Oncol · 2023-02-17

该文为《肿瘤学大查房》栏目对Miklos等试验的解读,指出在慢性移植物抗宿主病(cGVHD)一线治疗中,不应将伊布替尼加入糖皮质激素;糖皮质激素单药仍是cGVHD的标准一线治疗,伊布替尼、芦可替尼和贝鲁舒地尔仅被FDA批准用于激素难治性cGVHD。

要点

  • cGVHD一线标准治疗为糖皮质激素单药,加用吗替麦考酚酯或环孢素A均未改善缓解。
  • Miklos等试验数据表明,伊布替尼不应加入糖皮质激素用于cGVHD一线治疗。
  • 伊布替尼、芦可替尼和贝鲁舒地尔仅被FDA批准用于激素难治性cGVHD。

核心结论

  • 基于该试验,糖皮质激素单药仍是cGVHD的标准治疗。
  • 伊布替尼应保留用于二线治疗,这可能与其作用机制有关。
  • 未来研究应利用生物标志物或临床参数识别可能从糖皮质激素联合伊布替尼中获益的cGVHD患者。

研究设计与样本

  • 本文为《肿瘤学大查房》栏目对Miklos等发表于《临床肿瘤学杂志》的试验报告所作的临床解读,包含病例展示、诊疗挑战描述、相关文献回顾及作者建议的管理方法总结。

主要发现

  • cGVHD是异基因造血细胞移植后发生的免疫介导疾病,常累及多器官、降低生活质量并需要免疫抑制治疗。
  • 当前cGVHD一线标准治疗为糖皮质激素,其副作用显著。
  • 迄今所有通过加用其他药物(如吗替麦考酚酯或环孢素A)来改善一线糖皮质激素治疗cGVHD缓解的尝试均未改善缓解。
  • Miklos等试验报告的数据表明,伊布替尼不应加入糖皮质激素用于cGVHD一线治疗。
  • 伊布替尼、芦可替尼和贝鲁舒地尔是目前仅有的被美国食品药品监督管理局(FDA)批准用于激素难治性cGVHD的药物。

关键数值与推荐

  • cGVHD一线标准治疗为糖皮质激素单药。
  • 伊布替尼、芦可替尼和贝鲁舒地尔被FDA批准用于激素难治性cGVHD。
  • 基于该试验的建议是糖皮质激素单药仍为cGVHD的标准治疗。

临床怎么用

  • 基于该试验,糖皮质激素单药仍作为cGVHD的标准治疗。
  • 伊布替尼保留用于激素难治性cGVHD的二线治疗。
  • 未来研究可利用生物标志物或临床参数识别可能从糖皮质激素联合伊布替尼中获益的cGVHD患者。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The Oncology Grand Rounds series is designed to place original reports published in the Journal into clinical context. A case presentation is followed by a description of diagnostic and management challenges, a review of the relevant literature, and a summary of the authors' suggested management approaches. The goal of this series is to help readers better understand how to apply the results of key studies, including those published in Journal of Clinical Oncology, to patients seen in their own clinical practice.Chronic graft-versus-host disease (cGVHD) is an immune-mediated disease that ensues after allogeneic hematopoietic cell transplantation often affecting multiple organs, decreases quality of life, and necessitates immunosuppressive therapy. The current standard first-line cGVHD therapy is glucocorticoids (GCs) which have major side effects. So far, all attempts to improve response to first-line GC therapy of cGVHD by adding other agents, such as mycophenolate mofetil, or cyclosporine A have not improved response. The data reported in the trial by Miklos et al indicate that ibrutinib should not be added to GC in first-line cGVHD therapy. The findings instruct future studies that aim at the identification of patients with cGVHD who may benefit from a GC-ibrutinib combination using biomarkers or clinical parameters. Currently, ibrutinib, ruxolitinib, and belumosudil are the only drugs that are approved by the Food and Drug Administration for steroid-refractory cGVHD. In light of the current standard management of cGVHD, the trial results indicate that ibrutinib will remain reserved for second-line therapy, which may be due to its mechanisms of action. The recommendation on the basis of this trial is that GC monotherapy remains the standard therapy for cGVHD.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Zeiser R. Novel Approaches to the Treatment of Chronic Graft-Versus-Host Disease. J Clin Oncol. 2023. PMID: 36800551. doi:10.1200/JCO.22.02256

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。